Stay updated on Pembrolizumab vs Paclitaxel in Asian Gastric Cancer Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab vs Paclitaxel in Asian Gastric Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab vs Paclitaxel in Asian Gastric Cancer Clinical Trial page

  1. Check
    4 days ago
    No Change Detected
  2. Check
    11 days ago
    Change Detected
    Summary
    The site software version was updated from v3.4.3 to v3.5.0. No changes to study content or visible features are indicated.
    Difference
    0.0%
    Check dated 2026-03-25T20:39:54.000Z thumbnail image
  3. Check
    18 days ago
    No Change Detected
  4. Check
    25 days ago
    Change Detected
    Summary
    Revision label updated from v3.4.2 to v3.4.3. The change is limited to the page version tag and does not modify study details or content.
    Difference
    0.0%
    Check dated 2026-03-11T14:10:29.000Z thumbnail image
  5. Check
    54 days ago
    Change Detected
    Summary
    The page now includes a new site revision tag: Revision: v3.4.2. The older funding-status notice and the earlier Revision: v3.4.1 text have been removed.
    Difference
    0.3%
    Check dated 2026-02-11T02:19:51.000Z thumbnail image
  6. Check
    61 days ago
    Change Detected
    Summary
    Added a government funding lapse notice regarding NIH site status and updated the site revision to v3.4.1 (replacing v3.4.0).
    Difference
    0.3%
    Check dated 2026-02-04T00:45:27.000Z thumbnail image
  7. Check
    68 days ago
    Change Detected
    Summary
    A new 'Show glossary' option was added to the page interface, and several metadata labels were updated (e.g., 'Last Update Submitted that Met QC Criteria', 'No FEAR Act data') with the revision note showing 'Revision: v3.4.0'. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.2%
    Check dated 2026-01-27T23:42:20.000Z thumbnail image
  8. Check
    104 days ago
    Change Detected
    Summary
    Locations section expanded to list multiple new sites (Beijing Municipality, Fujian, Jiangsu, Jilin, Shanxi, Zhejiang, Kuala Lumpur, Gyeonggi-do) and corresponding individual location subsections were removed, along with the HHS Vulnerability Disclosure link.
    Difference
    0.7%
    Check dated 2025-12-23T01:46:08.000Z thumbnail image

Stay in the know with updates to Pembrolizumab vs Paclitaxel in Asian Gastric Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab vs Paclitaxel in Asian Gastric Cancer Clinical Trial page.